The early phase of the COVID-19 pandemic was associated with fewer patients receiving primary percutaneous coronary intervention (PPCI) and a higher hospital mortality for acute myocardial infarction in Europe. In this issue of Heart, De Luca and colleagues report the final results of the International Study on Acute Coronary Syndromes—ST Elevation Myocardial Infarction (ISACS-STEMI) Registry which included over 16 thousand patients presenting March to June 2020 at 109 high-volume PPCI centres in Europe, Latin America, South-East Asia and North Africa. Overall, there was a lower rate of PPCI in 2020 compared with 2019 with marked geographical heterogeneity; but no association between PPCI volumes and peak COVID-19 case or mortality rates (figure 1). The reduction in PPCI was greatest in older adults (age >75 years). Compared to 2019, the COVID-19 pandemic was associated with longer door-to-balloon times, total ischaemia time and higher in-hospital (6.5% vs 5.3%, p<0.001) and 30-day (8% vs 6.5%, p=0.001) mortality.

In the accompanying editorial, Cammann and Templin discuss the potential reasons for fewer patients presenting with an acute coronary syndrome during the pandemic, pointing out that this represents a failure to diagnosis and treat patients appropriately, not a reduction in disease prevalence. Delayed treatment or suboptimal intervention for acute coronary syndromes is likely to result in long-term detrimental consequences (figure 2). For those of us who trained in the early 1980s, the prevalence of postmyocardial infarction complications such as ventricular septal or papillary muscle rupture, ventricular thrombus, ischaemic cardiomyopathy, and arrhythmias is starting to look like the ‘not-so-good old days’.
sudden cardiac death (n=3) were the presence of a ventricular aneurysm and urinary 8-hydroxy-2′-deoxyguanosine (U-8-OHdG), a marker of oxidative DNA damage that reflects the inflammatory activity of CS. In patients with an U-8-OHdG level ≥14.9 ng/mg-Cr, the event rate per 100 patient-years was 0.6 (95% CI 0.015 to 3.303) compared with 12.3 (95% CI 6.739 to 20.681) in those with higher U-8-OHdG levels (figure 3).

In an editorial, Franke and Mahajan comment that “the results of this study show some promise for the use of urinary 8-OHdG in appropriate cohorts of patients with CS for risk stratification for primary prevention of SCD. Although this has exciting implications for the management of CS, particularly as urinary 8-OHdG is a simple, cost-effective test, larger, more robust studies are required to solidify its clinical use.”

Another study in this issue of Heart looked at predictors of heart failure (HF) in patients with a diagnosis of sarcoidosis. In the Swedish National Patient Registry, the rate of HF was 2.2/1000 patient-years in 8574 sarcoidosis patients compared with 0.7/1000 person-years in 84 192 matched general population cases. The risk of HF in sarcoidosis patients was not associated with age, sex or treatment status and was not explained by a history of ischaemic heart disease. Independent predictors of HF in patients with sarcoidosis were diabetes, atrial fibrillation and ventricular arrhythmias, suggesting that the presence of arrhythmias indicated cardiac involvement by sarcoidosis.

The Education in Heart article in this issue summarises the pathophysiology of tricuspid regurgitation, the options for treatment, and the current criteria for patient selection and optimal timing of transcatheter tricuspid valve intervention (figure 4). A review article on implications of cancer prior to and after heart transplantation provides a comprehensive review of the literature and practical guidance for clinical practice. Up to a third of heart transplant recipients are diagnosed with cancer with 10 years of transplantation which represents a 1.5- to 5-fold higher risk than the general population. In patients with cancer prior to heart transplantation, the risk of recurrence declines with the length of time in remission being only 5% if >5 years in remission versus a 63% recurrence rates if <1 year in remission. Another review article addresses the role of catheter ablation for management of atrial fibrillation in patients with heart failure. Atrial fibrillation and heart failure frequently coexist so that an integrated approach to treatment of both conditions is needed.

Figure 3 Risk stratification based on U-8-OHdG and ventricular aneurysm (VA). Patients showing U-8-OHdG concentration ≥14.9 ng/mg-Cr and presence of VA had a significantly highest risk of sVT/SCD (log-rank, p < 0.001 vs patients with neither, events per 100 patient-year, 31.0). SCD, sudden cardiac death; sVT, sustained ventricular tachycardia; U-8-OHdG, urinary 8-hydroxy-2′-deoxyguanosine; VA, ventricular aneurysm; VT, ventricular tachycardia.

Figure 4 General considerations regarding tricuspid valve therapy. The cornerstone of any TR therapy strategy is optimal heart failure therapy. Aside from diuretics (primarily loop diuretics and also sequential nephron blockade and aldosterone antagonists if permitted by renal function), no well-established guideline-recommendations for medical treatment exist specifically evaluated for TR therapy. Generally, TV repair is favoured over replacement. LV, left ventricle; RA, right atrium; RCA, right coronary artery; RV, right ventricle; sTR, secondary tricuspid regurgitation; TAVR, transcatheter aortic valve replacement; TMVR, transcatheter tricuspid valve repair/replacement; TOE, transoesophageal echocardiography; TTVR, transcatheter tricuspid valve repair/replacement; TV, tricuspid.
The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval This study does not involve human participants.

Provenance and peer review Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

To cite Otto CM. Heart 2022;108:407–409.

doi:10.1136/heartjnl-2022-320938

ORCID iD
Catherine M Otto http://orcid.org/0000-0002-0527-9392

REFERENCES